Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05020145 · ClinicalTrials.gov registry record
COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United States
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 1,277,747
- Enrollment target
NCT05020145 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 1,277,747 participants.
The verdict
NCT05020145 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 1,277,747 participants
- Enrollment target
Study Summary
This retrospective study will evaluate characteristics, vaccine utilization and outcomes among subjects with immunocompromising conditions that received COVID-19 vaccination.
Interventions
- BIOLOGICAL BNT162b2 (Tozinameran)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,277,747 participants |
| Start Date | 2021-08-25 |
| Est. Completion | 2021-12-17 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05020145
The ClinicalTrials.gov registry entry for NCT05020145 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,277,747 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BNT162b2 (Tozinameran) is the first listed.
NCT05020145 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05020145 about?
NCT05020145 is a clinical study titled "COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United States". This retrospective study will evaluate characteristics, vaccine utilization and outcomes among subjects with immunocompromising conditions that received COVID-19 vaccination.
What is the current status of trial NCT05020145?
This trial is currently completed. The enrollment target is 1,277,747 participants. The study started on 2021-08-25. Estimated completion is 2021-12-17.
What interventions are being tested in trial NCT05020145?
The interventions under investigation include: BNT162b2 (Tozinameran) (BIOLOGICAL).
Who is sponsoring clinical trial NCT05020145?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.